Company news
INVO Fertility, Inc. news in 2024
INVO Fertility, Inc.'s news releases, calls and decks from 2024, newest first.
NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma
October 23, 2024
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
October 20, 2024
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
October 13, 2024
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
August 13, 2024
INVO Reports Record First Quarter 2024 Financial Results
May 14, 2024
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
April 15, 2024
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
January 16, 2024